Pharma Focus Asia
KP - Choose our fully recyclable blister films

Breakthrough CMS I-neb® Therapy Discovered for Non-Cystic Fibrosis Bronchiectasis (NCFB)

Zambon discovered new CMS I-neb® therapy for the treatment of Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB).

Colistimethate sodium powder for nebulization solution (CMS I-neb®) is a unique investigational treatment developed as potential first-in-class inhaled therapy for adult patients with NCFB. It delivers targeted concentrations of drug directly to the disease thus minimising systemic exposure which can cause toxicity and side effects.

CMS I-neb® lowers the disease rates of pulmonary exacerbations in adult patients with non-cystic fibrosis bronchiectasis (NCFB).

NCFB is a chronic disease which is irreversible. Currently, there are no inhaled treatments approved for patients with bronchiectasis and chronic P. aeruginosa colonization.

In Phase 3 PROMIS - I study, the effect of CMS I-neb® has significantly reduced the rates of NCFB and P. aeruginosa chronic infections in patients. Moreover, the trial has shown significant results when compared to placebo in reducing severe exacerbations and in improving quality life’s of people.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoBora Pharmaceuticals - Free WhitepaperThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023
MasterControl - 6 Essential Features in an eQMS